Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Device, Expanded Patent Portfolio, and Further Clinical Studies
DIY Commercialization, with Olympic Ophthalmics’ Michael Gertner, MD.
2-Arctic-Vision-Announces-Exclusive-Licensing-Agreement with-Olympic-Ophthalmics-for-iTEAR®100-june6-2021
Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTEAR®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN Countries.
Olympic Ophthalmics Announces Issuance of Two Seminal Patents for its Neuromodulation Technology.
Clinical Results: Safety and Efficacy of iTEAR®100.
FDA Approval of iTEAR®100: An electromechanical nerve stimulator that is used externally on the nose and increases tear production.
Olympic Ophthalmics Receives FDA Clearance for iTEAR®100 Neurostimulator.
Dry Eye: The Nose Knows
Learn how neurostimulation is becoming a viable treatment option for patients who have exhausted their options.
Dry Eye Therapy: Getting Nosy
Understand the science behind nasal stimulation.

Ready to try iTEAR®100?

Get iTEAR®100

More questions?

iTEAR® Clinical Trial